Table 1.
Baseline table of patient characteristics, pharmacotherapy and outcome
| All (N = 1260) | FDCM (n = 238) | SDCM (n = 707) | P‐value a | |
|---|---|---|---|---|
| Age at diagnosis (years), median (IQR) | 49 (40–58) | 44 (31–52) | 51 (41–58) | <0.01 |
| Male | <0.05 | |||
| NYHA class | <0.01 | |||
| I | 935 (74%) | 165 (69%) | 536 (76%) | |
| II | 198 (19%) | 65 (35%) | 84 (14%) | |
| III | 448 (43%) | 79 (42%) | 261 (44%) | |
| IV | 316 (30%) | 37 (20%) | 187 (31%) | |
| Family history of SCD | 87 (8%) | 6 (3%) | 65 (11%) | <0.01 |
| Hypertension | 479 (38%) | 54 (23%) | 288 (41%) | <0.01 |
| Dyslipidaemia | 472 (38%) | 62 (26%) | 274 (39%) | <0.01 |
| Diabetes Mellitus | 211 (17%) | 25 (11%) | 127 (18%) | <0.01 |
| Alcohol use ≥ 1 units/day | 174 (16%) | 20 (10%) | 124 (20%) | <0.01 |
| Smoking (current and former) | 507 (42%) | 71 (31%) | 323 (47%) | <0.01 |
| Renal impairment | 172 (14%) | 24 (10%) | 94 (13%) | 0.20 |
| History of Atrial Fibrillation | 356 (28%) | 63 (27%) | 202 (29%) | 0.53 |
| History of Stroke | 87 (7%) | 12 (5%) | 47 (7%) | 0.38 |
| History of resuscitation | 61 (5%) | 15 (6%) | 32 (5%) | 0.28 |
| Atrioventricular block | 0.02 | |||
| 1st | 108 (9%) | 20 (9%) | 57 (8%) | |
| 2nd | 6 (1%) | 3 (1%) | 2 (0%) | |
| 3rd | 14 (1%) | 6 (3%) | 4 (1%) | |
| QRS Duration (ms), median, IQR | 105 (92–130) | 100 (90–112) | 104 (90–130) | 0.02 |
| LBBB | 219 (21%) | 18 (9%) | 133 (22%) | <0.01 |
| RBBB | 41 (4%) | 6 (3%) | 24 (4%) | 0.53 |
| LVEF (%), median (IQR) | 31 (25–40) | 37 (29–45) | 31 (24–40) | <0.01 |
| LVEDD (mm), median (IQR) | 64 (58–70) | 60 (54–67) | 64 (59–70) | <0.01 |
| Diastolic dysfunction (grades) | <0.01 | |||
| Normal | 63 (38%) | 97 (20%) | ||
| I (impaired relaxation) | 57 (35%) | 169 (35%) | ||
| II (pseudonormal) | 28 (17%) | 108 (22%) | ||
| III/IV (restrictive) | 16 (9%) | 109 (22%) | ||
| Haemoglobin (g/dL), median (IQR) | 14 (13–15) | 14 (13–15) | 14 (13–15) | 0.23 |
| BNP (pg/mL), median (IQR) | 297 (72–717) | 108 (36–555) | 404 (106–718) | 0.03 |
| NT‐proBNP (pg/mL), median (IQR) | 1102 (312–3341) | 589 (156–1663) | 1276 (452–3527) | <0.01 |
| Performed | 259 (21%) | 66 (28%) | 148 (21%) | 0.04 |
| Abnormal | 237 (19%) | 57 (24%) | 136 (19%) | 0.04 |
| Late gadolinium enhancement | 153 (64%) | 41 (65%) | 92 (67%) | 0.83 |
| β ‐blockers | 1130 (90%) | 203 (85%) | 644 (91%) | 0.01 |
| Diuretics | 895 (72%) | 123 (54%) | 540 (77%) | <0.01 |
| ACE‐inhibitors or ATII‐receptor blockers | 1121 (89%) | 208 (88%) | 634 (89%) | 0.329 |
| Mineralocorticoid receptor antagonists | 795 (63%) | 119 (50%) | 470 (67%) | <0.01 |
| Other antiarrhythmics | 361 (29%) | 56 (24%) | 215 (30%) | 0.04 |
BMI, body mass index; LBBB, left bundle branch block; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RBBB, right bundle branch block; SCD, sudden cardiac death.
Data are presented as number and percentages of valid. Patients with missing family status were not included in the subgroup SDCM in this table because their status was unknown. They have been included in the Supporting Information, Data S2 , Table 1 both a separate group and combined with SDCM. Continuous data are presented as medians. Median presented with first and third interquartiles (IQR). Mean presented with ±standard deviation (SD).
FDCM versus SDCM.